Clostridium difficile is a bacterial infection that commonly affects older adults and is recognized as the most prevalent healthcare-associated infection. The disease is characterized by symptoms such as diarrhea, nausea, colon inflammation, and more. The frequent use of antibiotics can contribute to contracting C. difficile by eliminating good bacteria and creating an environment favorable for C. difficile bacteria to multiply. Severe symptoms can lead to abdominal pain, distension, and profuse diarrhea.
The incidence of C. difficile infection has been on the rise due to recurrence and drug resistance. According to the Centers for Disease Control and Prevention (CDC) in 2015, approximately 500,000 Americans contract C. difficile infection each year. Similar trends have been observed in Canada and China, with significant numbers of patients affected by the infection. The increasing prevalence of antibiotic-resistant bacteria further contributes to the rising rates of infection. This scenario is expected to drive the growth of the global market for C. difficile diagnostics and treatments.
Request Sample Copy this Report:
We have an updated report [Version – 2023] available.
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
Our Sample Report May Includes:
• 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
• 100+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Requests.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
• Includes Updated List of tables & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.
Top Key Players:
★ Roche AG
★ Thermo Fisher Scientific Inc.
★ Merck & Co.
★ Pfizer Inc.
★ Actelion Pharmaceuticals
★ Alere Inc.
★ Trinity Biotech
★ Summit Therapeutics
★ Baxter International Inc.
★ Sanofi S.A.
★ Novartis AG
★ AstraZeneca Plc.
This report also splits the market by region:
Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East and Africa, Egypt, South Africa, Israel, Turkey, GCC Countries
Detailed Segmentation :
By Product Type:
- By Drug
- By Drug
By Diagnostic Test:
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
We Offer Customized Report, Click:
Over the projection period, increasing rates of clostridium difficile infection are anticipated to boost market expansion.
Due to clostridium difficile infection recurrence and drug resistance, the incidence of clostridium difficile infection has been on the rise recently.
According to the Centers for Disease Control and Prevention (CDC) in 2015, approximately 500,000 Americans contract clostridium difficile infection each year. Additionally, in 2012, there were roughly 37,900 patients in Canada who had the infection, as reported by the National Center for Biotechnology Information (NCBI). The NCBI also published a study and meta-analysis of studies completed in China between 2010 and 2016, which showed a significant incidence of clostridium difficile infection in China. Furthermore, the 2017 Report from the Canadian Antimicrobial Resistance Surveillance System suggests that taking antibiotics for unrelated conditions may lead to clostridium difficile infection. Antibiotic-resistant microorganisms are common in G7 nations, according to the Organization for Economic Co-operation and Development (OECD) in 2015. The increasing prevalence of antibiotic-resistant bacteria may contribute to rising rates of infection, which is expected to drive the growth of the global market for clostridium difficile diagnostics and treatments.
In 2016, the global market for clostridium difficile diagnostics and treatment was worth US$ 1,272.2 million, and it is projected to experience a strong compound annual growth rate (CAGR) of 8.2% from 2017 to 2025.
The clostridium difficile treatment market is anticipated to experience growth during the forecast period, owing to a strong pipeline of various therapies.
For the treatment of clostridium difficile infection (CDI), antibiotics such as metronidazole, Vancomycin, and Fidaxomicin have been traditionally used. Unfortunately, these drugs remain the only option available for CDI patients, except for surgery in severe cases, fecal microbiota transplant, and probiotics in cases of recurrent CDI. However, various manufacturers, including Rebiotix, Inc., Synthetic Biologics, Inc., Da Volterra, Crestovo LLC, and Immuron Ltd. have a promising pipeline of microbiome therapeutics (a new class of drugs) for CDI. For instance, Rebiotix, Inc.’s RBX7455 capsule is currently in Phase 1 clinical trials, Synthetic Biologics Inc.’s SYN-004 (ribaxamase) is in Phase 2 clinical trials, and Da Volterra has DAV132 in clinical trials for antibiotic-induced CDI. If these drugs pass the clinical trials successfully, they could provide an alternative to conventional antibiotics for the treatment of the disease. Additionally, probiotics are gaining traction as they restore the natural balance of bacteria in the gut, allowing the growth of natural flora. Pfizer, Inc. and Valneva are developing novel vaccines for the treatment of CDI. Pfizer, Inc.’s recombinant TcdA and TcdB PF-06425090 vaccine is currently in Phase 2 trials, while Valneva’s VLA84 is in Phase 1 trials.
The market for clostridium difficile diagnostics and treatment is anticipated to develop over the forecast period, but it will be constrained by low awareness of the symptoms and effects of clostridium difficile infection.
Purchase This Complete Business Report:
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Clostridium Difficile Diagnostics and Treatment Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Clostridium Difficile Diagnostics and Treatment Industry Impact
Chapter 2 Global Clostridium Difficile Diagnostics and Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Clostridium Difficile Diagnostics and Treatment (Volume and Value) by Type
2.3 Global Clostridium Difficile Diagnostics and Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Clostridium Difficile Diagnostics and Treatment Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 6 East Asia Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 7 Europe Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 8 South Asia Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 9 Southeast Asia Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 10 Middle East Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 11 Africa Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 12 Oceania Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 13 South America Clostridium Difficile Diagnostics and Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Clostridium Difficile Diagnostics and Treatment Business
Chapter 15 Global Clostridium Difficile Diagnostics and Treatment Market Forecast (2023-2030)
Chapter 16 Conclusions
Explore More Related Insights:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027